The American Medical Association declared its support for H.R. 4317, the PBM Reform Act, in a letter to two of the members of the House of Representatives who introduced the bill, Reps. Buddy Carter (R-Ga.) and Debbie Dingell (D-Mich.).
AMA CEO John Whyte, MD, MPH, wrote that the bill’s provisions “would promote greater transparency around PBM polices and their impact on patients, physicians, employers, pharmacies, and other stakeholders throughout the pharmaceutical distribution system.”
“By prioritizing transparency, competitive markets, and enforceable protections for patients this legislation restores integrity to our prescription drug system. It is a vital move toward lowering out-of-pocket costs, safeguarding access, and delivering on the promise of affordable care,” he said.
You can read the letter here.
